Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant

Data herein reported and discussed refer to vaccination with the recombinant fatty acid binding protein (FABP) family member of the schistosomes, called Sm14. This antigen was discovered and developed under a Brazilian platform led by the Oswaldo Cruz Foundation, from the Health Ministry in Brazil,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tendler, Miriam, Almeida, Marilia, Simpson, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429245/
https://www.ncbi.nlm.nih.gov/pubmed/26029206
http://dx.doi.org/10.3389/fimmu.2015.00218
_version_ 1782371007456083968
author Tendler, Miriam
Almeida, Marilia
Simpson, Andrew
author_facet Tendler, Miriam
Almeida, Marilia
Simpson, Andrew
author_sort Tendler, Miriam
collection PubMed
description Data herein reported and discussed refer to vaccination with the recombinant fatty acid binding protein (FABP) family member of the schistosomes, called Sm14. This antigen was discovered and developed under a Brazilian platform led by the Oswaldo Cruz Foundation, from the Health Ministry in Brazil, and was assessed for safety and immunogenicity in healthy volunteers. This paper reviews past and recent outcomes of developmental phases of the Sm14-based anti schistosomiasis vaccine addressed to, ultimately, impact transmission of the second most prevalent parasitic endemic disease worldwide.
format Online
Article
Text
id pubmed-4429245
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44292452015-05-29 Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant Tendler, Miriam Almeida, Marilia Simpson, Andrew Front Immunol Immunology Data herein reported and discussed refer to vaccination with the recombinant fatty acid binding protein (FABP) family member of the schistosomes, called Sm14. This antigen was discovered and developed under a Brazilian platform led by the Oswaldo Cruz Foundation, from the Health Ministry in Brazil, and was assessed for safety and immunogenicity in healthy volunteers. This paper reviews past and recent outcomes of developmental phases of the Sm14-based anti schistosomiasis vaccine addressed to, ultimately, impact transmission of the second most prevalent parasitic endemic disease worldwide. Frontiers Media S.A. 2015-05-12 /pmc/articles/PMC4429245/ /pubmed/26029206 http://dx.doi.org/10.3389/fimmu.2015.00218 Text en Copyright © 2015 Tendler, Almeida and Simpson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tendler, Miriam
Almeida, Marilia
Simpson, Andrew
Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
title Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
title_full Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
title_fullStr Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
title_full_unstemmed Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
title_short Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
title_sort development of the brazilian anti schistosomiasis vaccine based on the recombinant fatty acid binding protein sm14 plus gla-se adjuvant
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429245/
https://www.ncbi.nlm.nih.gov/pubmed/26029206
http://dx.doi.org/10.3389/fimmu.2015.00218
work_keys_str_mv AT tendlermiriam developmentofthebrazilianantischistosomiasisvaccinebasedontherecombinantfattyacidbindingproteinsm14plusglaseadjuvant
AT almeidamarilia developmentofthebrazilianantischistosomiasisvaccinebasedontherecombinantfattyacidbindingproteinsm14plusglaseadjuvant
AT simpsonandrew developmentofthebrazilianantischistosomiasisvaccinebasedontherecombinantfattyacidbindingproteinsm14plusglaseadjuvant

Ejemplares similares